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Abstract
Background: Lafutidine is a histamine H2 receptor antagonist, the gastroprotective effect of which
is related to its antisecretory activity and its ability to activate a sensory neuron-dependent
mechanism of defence. The present study investigated whether intragastric administration of
lafutidine (10 and 30 mg/kg) modifies vagal afferent signalling, mucosal injury, intragastric acidity and
gastric emptying after gastric acid challenge.
Methods: Adult rats were treated with vehicle, lafutidine (10 – 30 mg/kg) or cimetidine (10 mg/
kg), and 30 min later their stomachs were exposed to exogenous HCl (0.25 M). During the period
of 2 h post-HCl, intragastric pH, gastric volume, gastric acidity and extent of macroscopic gastric
mucosal injury were determined and the activation of neurons in the brainstem was visualized by
c-Fos immunocytochemistry.
Results: Gastric acid challenge enhanced the expression of c-Fos in the nucleus tractus solitarii but
caused only minimal damage to the gastric mucosa. Lafutidine reduced the HCl-evoked expression
of c-Fos in the NTS and elevated the intragastric pH following intragastric administration of excess
HCl. Further analysis showed that the gastroprotective effect of lafutidine against excess acid was
delayed and went in parallel with facilitation of gastric emptying, measured indirectly via gastric
volume changes, and a reduction of gastric acidity. The H2 receptor antagonist cimetidine had
similar but weaker effects.
Conclusion: These observations indicate that lafutidine inhibits the vagal afferent signalling of a
gastric acid insult, which may reflect an inhibitory action on acid-induced gastric pain. The ability of
lafutidine to decrease intragastric acidity following exposure to excess HCl cannot be explained by
its antisecretory activity but appears to reflect dilution and/or emptying of the acid load into the
duodenum. This profile of actions emphasizes the notion that H2 receptor antagonists can protect
the gastric mucosa from acid injury independently of their ability to suppress gastric acid secretion.
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Exposure of the gastric mucosa of conscious rats to excess
HCl (0.25 M) is signalled, via vagal afferents, to the
nucleus tractus solitarii (NTS) in the brainstem, where
neuronal activation can be visualized by c-fos mRNA in-
situ hybridization and c-Fos immunocytochemistry [1,2].
Analysis of the behavioural reactions to gastric acid chal-
lenge indicates that vagal afferent neurons play an impor-
tant role in gastric acid nociception [3]. The vagal afferent
signalling of gastric acid challenge is known to be inhib-
ited by morphine [1], by a combination of glutamate
NMDA and tachykinin NK1 and NK2 receptor antagonists
[4] and by antisecretory agents such as cimetidine and
omeprazole [2].
Like cimetidine, lafutidine is a histamine H2 receptor
antagonist which has been shown to protect from acid-
related gastric injury in rodents [5-8]. In addition, there is
evidence that the gastroprotective action of lafutidine
involves release of neuropeptides from afferent nerve end-
ings in the stomach [7,8]. In view of this pharmacological
profile the question arose as to whether lafutidine would
be able to modify vagal afferent signalling of gastric acid
challenge to the brainstem. Therefore, the first aim of this
study was to test the effect of lafutidine on gastric acid-
evoked expression of c-Fos in the rat brainstem. In addi-
tion, the gastric pH was recorded and the degree of mac-
roscopic gastric injury quantified.
In the course of these experiments it was discovered that
lafutidine facilitates the removal of the exogenous acid
load from the stomach. Since secretion of endogenous
gastric acid is suppressed by an exogenous acid load, the
action of lafutidine to raise intragastric pH cannot be
explained by its antisecretory activity due to histamine H2
receptor blockade. As a consequence, this effect of lafuti-
dine is likely to reflect dilution and/or emptying of the
acid load into the duodenum. This reasoning is supported
by the observation that exposure of the stomach to excess
acid inhibits gastric emptying and causes fluid secretion
[2,9]. The second aim of this study was hence to explore
whether lafutidine modifies the time course of gastric
injury, gastric volume and gastric acidity following an
exogenous acid load and whether any influence of lafuti-
dine on these parameters is shared by cimetidine.
Methods
Animals
The study was carried out with female age-matched
Sprague-Dawley rats (Division of Laboratory Animal Sci-
ence and Genetics, Department of Biomedical Research,
Medical University of Vienna, Himberg, Austria) weighing
170 – 250 g. The animals were housed in groups of 3 per
cage under controlled temperature (21°C) and a 12 h
light/dark cycle (lights on at 6:00, lights off at 18:00). All
experiments were approved by an Ethical Committee at
the Federal Ministry of Science and Research and con-
ducted according to the Directive of the European Com-
munities Council of 24 November 1986 (86/609/EEC).
The experiments were designed in such a way that the
number of animals used and their suffering was mini-
mized.
Experimental protocols
Two studies were carried out. Seven days before the gastric
acid loading experiment, the animals were randomly
assigned to treatment groups using a randomization soft-
ware (Randomizer for Clinical Trials 1.8.0, Institute of
Medical Informatics, Statistics and Documentation, Med-
ical University Graz, Austria). On the day before the acid
loading experiment, the rats were deprived of food and
fasted for 18 h to ensure that the stomach was empty, but
had free access to water. In the first study, the effects of
two doses of lafutidine (10 and 30 mg/kg) on gastric acid-
evoked c-Fos expression in the brainstem of conscious rats
was examined along with gastric acidity and injury. Lafu-
tidine or its vehicle (0.5% carboxymethyl cellulose) was
administered perorally 30 min before the stomach was
exposed to a noxious concentration of acid (0.25 M HCl)
by gavage. After the intragastric treatment the animals
were no longer allowed to drink until recording of the
experimental parameters. Two hours after gastric acid
loading the number of c-Fos-immunoreactive neurons in
the brainstem, intragastric pH and the extent of macro-
sopic gastric mucosal injury were determined.
In the second experiment, the effects of a single dose of
lafutidine (30 mg/kg) or cimetidine (10 mg/kg) on the
time course of gastric volume, acidity and injury after
exposure to an exogenous acid load were examined. The
drugs as well as their vehicle were administered intragas-
trically by gavage 30 min before the stomach was exposed
to HCl. After the intragastric treatment the animals were
no longer allowed to drink until recording of the experi-
mental parameters. Gastric volume, acidity and injury
were quantified at 3 time points after administration of
the intragastric acid load: 0, 60 and 120 min. All parame-
ters were recorded in the same experiments.
Lafutidine and cimetidine treatments
Lafutidine (Taiho, Tokyo, Japan) and cimetidine (Sigma,
Vienna, Austria) were suspended in carboxymethyl cellu-
lose (0.5%) at a concentration of 2 and 6 mg/ml (lafuti-
dine) and 2 mg/ml (cimetidine). Lafutidine (10 and 30
mg/kg), cimetidine (10 mg/kg) or its vehicle was admin-
istered perorally by gavage at a volume of 5 ml/kg 30 min
before the stomach was exposed to HCl. The intragastric
administration was carried out with a soft infant feeding
tube (outer diameter 2.6 mm; SIMS Portex, Hythe, United
Kingdom).Page 2 of 11
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HCl (0.25 M) was administered intragastrically at a vol-
ume of 10 ml/kg through the same soft infant feeding
tube that was used for administration of lafutidine. After
this intragastric acid loading the animals were no longer
allowed to drink until recording of the experimental
parameters.
c-Fos immunocytochemistry
c-Fos-like immunoreactivity was visualized as described
previously [2,10]. Two hours after intragastric acid load-
ing, the rats were euthanized by intraperitoneal injection
of an overdose of pentobarbital (200 mg/kg). Following
euthanasia, the animals were transcardially perfused with
buffered paraformaldehyde (4%, 75 ml) while the
descending aorta was clamped. The brainstems were
removed and postfixed overnight in buffered paraformal-
dehyde (4%) at 4°C. Then the tissues were cryoprotected
for 48 h in 20% sucrose at 4°C, frozen by immersion in
methylbutane on dry ice and stored at -70°C until use.
Serial coronal sections of 40 μm thickness were cut from
the brainstem over the whole length of the area postrema
(AP) with a cryostat.
Immunocytochemistry was performed with free-floating
sections which first were washed once in 0.1 M phos-
phate-buffered saline (PBS), then washed twice in wash-
ing buffer (WB; 0.1 M PBS with 0.3% Triton X 100), and
incubated in 0.3% H2O2 for 30 min. After three further
washes (each for 10 min in WB), the tissues were incu-
bated with the primary antibody (rabbit polyclonal anti-
c-Fos, 1:20,000, Santa Cruz Biotech, Santa Cruz, Califor-
nia, USA) for 40 h at 4°C. This antibody was dissolved in
0.1 M PBS containing 0.3% Triton X 100, 1% bovine
serum albumin and 2.5% goat serum. Afterwards the sec-
tions were washed three times in WB and incubated for 45
min in a solution containing the biotinylated secondary
antibody (goat anti-rabbit IgG, Vectastain Elite Kit, Vector
Laboratories, Burlingame, California, USA). After three
other washes in WB they were incubated for 1 h in avidin-
biotin complex (Vectastain Elite Kit). The tissues were
rinsed afterwards and developed with 3,3-diaminobenzi-
dine (DAB) substrate (Vectastain Elite Kit) intensified
with nickel sulfate for 200 s. Subsequently the sections
were mounted on gelatin-covered slides, air-dried and
cleared in xylol (100%). The slides were coverslipped with
Entellan (Merck, Darmstadt, Germany). To control for the
specificity of the anti-c-Fos antibody signal, a c-Fos block-
ing peptide (Santa Cruz Biotech) was added to the pri-
mary antibody dilution.
The immunocytochemically processed brainstem sections
were examined with a light microscope (Axiophot, Zeiss,
Oberkochen, Germany) coupled to a computerized image
analysis system (MCID-M2, version 3.0, Rev 1.1, Imaging
Research Inc., Brock University, St. Catharines, Ontario,
Canada). The sections were coded such that the examiner
did not know which treatment group they came from.
Four sections from the brainstem of each animal were
analysed, and all c-Fos-positive cells were randomly
counted on one side of the NTS and AP. In order to avoid
that the same cells were counted twice, only every second
section was taken for analysis. All counts in each section
of each animal were averaged to give the number of c-Fos-
positive cells in the NTS and AP of that animal. These aver-
age values from each animal were then used to calculate
the mean number of c-Fos-positive cells per section in the
unilateral NTS and AP of each experimental group.
Determination of gastric volume
The rats were euthanized by intraperitoneal injection of
an overdose of pentobarbital (200 mg/kg) immediately (0
min), 60 or 120 min after intragastric acid loading. Fol-
lowing exposure of the stomach by a midline laparotomy,
the cardia and pylorus were clamped. The stomach was
excised and weighed (weight 1). After collecting its con-
tent in a vial, the stomach was re-weighed (weight 2). The
volume of the gastric content was calculated by the differ-
ence weight 2 – weight 1 and expressed relative to the
body weight (g/kg body weight). In addition, the gastric
volume recovered 60 and 120 min after gastric acid load-
ing was also expressed relative to the volume measured
immediately (0 min) after gastric acid loading.
Intragastric pH
Following euthanasia, the abdomen was opened by a
midline laparotomy. The stomach was excised and
opened, and the intragastric pH was determined with a
pH meter that was fitted with a Micro Line pH electrode
(ThermoOrion, New Hyde Park, NY, USA) and calibrated
with standard buffers of pH 4.01, 7.00 and 10.00.
Titration of gastric contents
The gastric contents were emptied into tubes, briefly cen-
trifuged at 5,600 × g (10,000 rpm) and diluted 1:10, 1:25
or 1:50 in 5 ml distilled water, the dilution rate depending
on the volume of the gastric contents that were recovered.
If no gastric juice was recovered, the appropriate amount
of chyme was used. Titration was performed with 0.1 M
NaOH on a Titroline Alpha Titration Apparatus (Schott-
Geräte GmbH, Hofheim, Germany) until the endpoint of
pH = 7.0 was reached. The amount of acid equivalents
present in the stomach was calculated as mmol, and gas-
tric acidity measured 60 and 120 min after gastric acid
loading was also expressed relative to the acidity meas-
ured immediately (0 min) after gastric acid loading.
Gastric injury
The integrity of the gastric mucosa was examined at the
macroscopic level. To quantify macroscopically visiblePage 3 of 11
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tomer-coated plate and covered with PBS. The stomach
was photographed, the image transferred to a personal
computer, and macroscopic gastric injury assessed with
computerized planimetry by an observer who was una-
ware of the experimental treatment [1]. The mucosal area
covered by visible haemorrhagic damage was expressed as
a percentage of the total area of the glandular mucosa.
Statistics
Statistical evaluation of the results was performed on SPSS
15.0 (SPSS Inc., Chicago, IL, USA) with one-way analysis
of variance (ANOVA). These tests were carried out despite
the fact that the data of some experimental groups did not
meet the criterion of normal distribution, because this
limitation was explained by the limited number of ani-
mals per group and because there was no reason to
assume a non-normal distribution. The homogeneity of
variances was assessed with the Levene test. If a significant
interaction between the test factors was found, post-hoc
analysis of group differences was made with the Tukey
HSD (honestly significant difference) test or, in case of
inhomogeneity of variances, with the Games-Howell test.
All data are presented as means ± SEM, n referring to the
number of rats in each group. In view of the exploratory
nature of the study, probability values ≤ 0.1 [11,12] were
regarded as statistically significant.
Results
Study 1: Effects of lafutidine on c-Fos expression in the 
brainstem, intragastric pH and gastric mucosal injury after 
intragastric acid loading
Exposure of the rat gastric mucosa to HCl (0.25 M)
enhanced the expression of c-Fos in the NTS and AP to a
significant extent (Figures 1A, B and 2A, B) but, relative to
saline, did not cause any significant gastric mucosal dam-
age (Danzer et al. 2004). A similar observation was made
in the present study, given that on average less than 0.2%
of the glandular mucosa presented with macroscopic
abnormalities, mostly petechiae (Figure 2C). While the
pH of the HCl solution administered intragastrically was
0.51, the pH in the gastric juice 2 h after HCl challenge
had risen to more than 2.5 (Figure 2D).
Following intragastric administration of lafutidine (10
and 30 mg/kg), the area of gastric injury was nominally
reduced but this effect did not reach statistical significance
(Figure 2C). In contrast, intragastric pH was increased by
either dose of lafutidine (Figure 2D) to a significant extent
as revealed by one-way ANOVA (F(2,20) = 11.08, P < 0.001)
and the post-hoc test. The acid-evoked expression of c-Fos
in the NTS (Figures 1A, B and 2A) was reduced by lafuti-
dine (10 and 30 mg/kg), and one-way ANOVA disclosed
this effect to be statistically significant (F(2,19) = 4.30, P =
0.029). To the contrary, the ability of lafutidine to attenu-
ate acid-evoked expression of c-Fos in the AP did not reach
statistical significance (Figures 1A, B and 2B).
Study 2: Effects of lafutidine on the time course of gastric 
volume, acidity and injury after intragastric acid loading
As in study 1, challenge of the stomach with 0.25 M HCl
caused minor macroscopic damage which on average cov-
ered less than 0.2% of the area of the glandular mucosa
(Figure 3A). The extent of damage did not significantly
differ between the time points 0, 60 and 120 min post-
HCl in vehicle- and cimetidine-treated rats. In lafutidine-
treated rats, however, the extent of damage 120 min after
acid challenge was significantly smaller than immediately
after gastric acid loading (Figure 3A).
The amount of acid equivalents present in the gastric
lumen fell significantly over the 2 h interval post-HCl in
all treatment groups (Figure 3B). Most of the drop in gas-
tric acidity occurred within 60 min post-HCl, and there
was no significant difference in the gastric acidity levels 0
and 60 min post-HCl between the three treatment groups.
In lafutidine-treated rats there was a further significant
drop of gastric acidity during the period 60 – 120 min
Gastric acid-evoked expression of c-Fos in the nucleus trac-tus solit r i (NTS) and area p strema (AP) in a rat treated with vehi le (A) an another ra  tre ted wi  laf idine (B)Figu 1
Gastric acid-evoked expression of c-Fos in the 
nucleus tractus solitarii (NTS) and area postrema 
(AP) in a rat treated with vehicle (A) and another rat 
treated with lafutidine (B). Lafutidine (30 mg/kg) or its 
vehicle (0.5% carboxymethyl cellulose) was administered 
perorally 30 min before the stomach was exposed to an 
exogenous acid load (0.25 M HCl). Two hours post-HCl c-
Fos-positive cells in the brainstem were visualized by immu-
nocytochemistry.Page 4 of 11
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Effect of lafutidine (10 and 30 mg/kg), relative to vehicle, on the number of c-Fos positive cells in (A) the nucleus tractus soli-tarii (NTS) an  (B) are  postrema (AP), (C) macroscopic gastric mucosal injury (expressed as a percentage of the area of the glandular m cosa) and (D) intra stric pH measur d 2 h after xposure f the stomach to HCl (0.25 M)Figure 2
Effect of lafutidine (10 and 30 mg/kg), relative to vehicle, on the number of c-Fos positive cells in (A) the 
nucleus tractus solitarii (NTS) and (B) area postrema (AP), (C) macroscopic gastric mucosal injury (expressed 
as a percentage of the area of the glandular mucosa) and (D) intragastric pH measured 2 h after exposure of 
the stomach to HCl (0.25 M). Lafutidine or vehicle was administered by gastric gavage 30 min before administration of HCl. 
The values represent means + SEM, n = 8 if not stated otherwise. * P ≤ 0.1, ** P ≤ 0.05 versus vehicle.
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tidine-treated rats (Figure 3B). The decrease in gastric acid-
ity 120 min post-HCl in lafutidine-treated rats was
significantly more marked than in vehicle-treated animals
(Figure 3B). When gastric acidity measured 60 and 120
min post-HCl was expressed relative to the acidity meas-
ured immediately (0 min) after gastric acid loading, it was
found that the drop of gastric acidity 120 min post-HCl
seen in lafutidine-treated rats was most pronounced, com-
pared with that seen in vehicle- and cimetidine-treated
rats (Figure 4A).
The weight of the gastric content relative to the body
weight (g/kg) was calculated as an indirect measure of gas-
tric emptying. As shown in Figure 3C, the gastric content
weight fell significantly over time in all treatment groups
and 60 as well as 120 min post-HCl was significantly
smaller than immediately after gastric acid loading. Lafu-
tidine- and cimetidine-treated rats differed from vehicle-
treated rats in two aspects. First, immediately after acid
challenge the gastric content weight was significantly
higher in lafutidine- and cimetidine-treated animals than
in control rats (Figure 3C). Second, when measured 120
min post-HCl in lafutidine- and cimetidine-treated ani-
mals, this parameter was significantly lower than that
measured 60 min post-HCl, whereas in vehicle-treated
rats the gastric content weights recorded 60 and 120 min
post-HCl were not significantly different from each other
(Figure 3C).
Since the initial gastric volume in lafutidine- and cimeti-
dine-treated animals was higher than in control rats (Fig-
ure 3C), the time course of gastric volume changes in the
different treatment groups is difficult to compare with
each other because it might be differentially influenced by
the initial volume. For this reason, the gastric contents
recovered 60 and 120 min post-HCl were also expressed
as a percentage of the volume measured immediately (0
min) after gastric acid loading (Figure 4). In this way it
was found that the decrease in gastric volume 120 min
post-HCl in lafutidine-treated rats was more pronounced
than in vehicle-treated rats (Figure 4B).
Discussion
The major results of the current study can be summarized
as follows. Lafutidine inhibits the vagal afferent signalling
of a gastric acid insult, which raises the possibility that
lafutidine inhibits acid-induced gastric pain. The ability of
lafutidine to decrease intragastric acidity following expo-
sure to excess HCl cannot be explained by its antisecretory
activity and is likely to reflect dilution and/or emptying of
the acid load into the duodenum.
Vagal afferent signalling of a gastric acid insult was visual-
ized by c-Fos expression in the medullary brainstem, a
standard method in functional neuroanatomy to deline-
ate stimulus-evoked activation of neurons [13,14]. In this
way it has previously been shown that exposure of the rat
stomach to excess concentrations of HCl stimulates neu-
rons in the brainstem [1,2]. The appearance of the c-Fos
protein was measured 2 h post-HCl, given that the trans-
lation of c-fos mRNA into c-Fos protein reaches its maxi-
mum between 1 and 3 h post-stimulus [2]. We limited our
analysis to the brainstem, because exposure of the rat
stomach to HCl failed to induce any c-fos mRNA and c-
Fos protein in the dorsal horn of the posterior thoracic
spinal cord which receives gastric input via spinal afferent
neurons [1,2]. These data and the ability of chronic bilat-
eral subdiaphragmatic vagotomy to suppress gastric acid-
evoked expression of c-fos mRNA [1] indicate that gastric
challenge with HCl is signalled to the brainstem via vagal
afferents.
The induction of c-fos mRNA and c-Fos protein in the
NTS, the central projection area of vagal afferents, is
related to the intragastrically administered HCl concentra-
tion [1,2]. A comparative analysis of the medullary c-Fos
induction and gastric damage indicates that the afferent
signalling of gastric acid challenge is not directly related to
the formation of overt mucosal injury, since c-Fos expres-
sion in the NTS can be evoked by HCl concentrations
(0.15 – 0.35 M) that do not induce any appreciable mac-
roscopic lesions and cause little histological damage [1,2].
Because supraphysiological concentrations of HCl (0.15
M or higher) are required to induce c-Fos in the NTS, it has
been inferred that only a massive increase in the proton
gradient across the acid-tight gastric mucosal barrier is
Effect of lafutidine (30 mg/kg) and cimetidine (10 mg/kg), relative to vehicle, on (A) macroscopic gastric mucosal injury (expressed as a percentage of the area of the glandular mucosa), (B) intragastric acidity (acid equivalents in mmol) and (C) weight of gastr c content (g/kg body we ght) me sured i mediately (0 min), 60 and 120 min after exposure f the stomach to HCl (0.25 M)Figure 3 (see pr vious p ge)
Effect of lafutidine (30 mg/kg) and cimetidine (10 mg/kg), relative to vehicle, on (A) macroscopic gastric 
mucosal injury (expressed as a percentage of the area of the glandular mucosa), (B) intragastric acidity (acid 
equivalents in mmol) and (C) weight of gastric content (g/kg body weight) measured immediately (0 min), 60 
and 120 min after exposure of the stomach to HCl (0.25 M). Lafutidine, cimetidine or vehicle was administered by gas-
tric gavage 30 min before administration of HCl. The values represent means + SEM, n = 8. ** P ≤ 0.05 versus time 0 min under 
the same treatment, + P ≤ 0.1, ++ P ≤ 0.05 versus time 60 min under the same treatment, °P ≤ 0.1, °°P ≤ 0.05 versus vehicle at 
the same time point post-HCl.Page 7 of 11
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Effect of lafutidine (30 mg/kg) and cimetidine (10 mg/kg), relative to vehicle, on (A) intragastric acidity and (B) weight of gastric content measured 60 and 120 min aft r exposure of the stomach to HCl (0.25 M and expressed as a percentage of the resp ctive val es measured im edia ly aft r gastric acid l ading (0 min)Figure 4
Effect of lafutidine (30 mg/kg) and cimetidine (10 mg/kg), relative to vehicle, on (A) intragastric acidity and (B) 
weight of gastric content measured 60 and 120 min after exposure of the stomach to HCl (0.25 M) and 
expressed as a percentage of the respective values measured immediately after gastric acid loading (0 min). 
Lafutidine, cimetidine or vehicle was administered by gastric gavage 30 min before administration of HCl. The values represent 
means + SEM, n = 8. ** P ≤ 0.05 versus time 0 min under the same treatment, + P ≤ 0.1, ++ P ≤ 0.05 versus time 60 min under 
the same treatment, °P ≤ 0.1, °°P ≤ 0.05 versus vehicle at the same time point post-HCl.
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where they can excite vagal afferent nerve fibres either
directly or indirectly via neuroactive factors released in the
tissue [2]. This experimental setup is thus thought to
model pathophysiological circumstances where backdif-
fusion of luminal acid stimulates vagal afferents.
The data of the current study show that lafutidine admin-
istered intragastrically at doses (10 and 30 mg/kg) found
previously to be gastroprotective [5,6,15] reduced the
afferent signalling of a gastric acid insult to the NTS. This
observation is consistent with the ability of another hista-
mine H2 receptor antagonist, cimetidine, and the proton
pump inhibitor omeprazole to reduce gastric acid-evoked
expression of c-Fos in the rat brainstem [2]. Since the
behavioural reactions to gastric acid challenge indicate
that the c-Fos expression in the NTS is a correlate of gastric
acid nociception [2,3] it can be proposed that lafutidine
has an inhibitory effect on gastric chemonociception. This
antinociceptive effect, however, is unlikely to be
explained by the antisecretory activity of lafutidine, given
that exposure of the gastric mucosa to excess exogenous
acid such as 0.25 M HCl will by itself suppress endog-
enous acid secretion by a negative feedback mechanism
[16-19]. As a consequence, two alternative explanations
need to be envisaged.
One explanation that comes to mind is to assume that
lafutidine, like cimetidine [2], interferes with vagal affer-
ent pathways that signal acid challenge of the gastric
mucosa to the brainstem. Lafutidine may do so (1) by
inhibiting the stimulation of vagal afferent neurons by
acid intruding the gastric mucosa, (2) by depressing signal
conduction in vagal afferent neurons, (3) by blocking syn-
aptic transmission between the central endings of vagal
afferents and NTS neurons and/or (4) by reducing the
excitability of the brainstem neurons expressing c-Fos in
response to input from the stomach.
Which of these possibilities applies to the effects of lafuti-
dine and cimetidine requires identification of the site of
action where H2 receptor antagonists interfere with affer-
ent vagal pathways. It has previously been shown that
vagal afferent neurons that signal gastric acid challenge to
the NTS are insensitive to the neurotoxic effect of capsai-
cin [1] and that the activation of this pathway by acid is
independent of prostaglandins [20]. The vagal afferent
system inhibited by lafutidine thus appears to be funda-
mentally different from that of capsaicin-sensitive spinal
afferent neurons which are thought to mediate the ability
of lafutidine to protect the gastrointestinal mucosa from
injury [6-8,15,21-23]. While vagal afferents appear to be
inhibited via a H2 receptor-dependent mechanism, capsa-
icin-sensitive spinal afferents are activated or sensitized by
lafutidine, but not other H2 receptor antagonists, which
results in the release of the protective messenger calci-
tonin gene-related peptide [6-8,15,21-23]. Prostaglandins
may also play a role in the gastroprotective effect of lafu-
tidine against stress [23].
Another explanation for the inhibitory effect of lafutidine
on the gastric acid-evoked c-Fos expression in the brain-
stem takes into account that lafutidine significantly
decreased the acidity of the exogenous gastric acid load.
By whatever mechanism lafutidine facilitates the elimina-
tion of the gastric acid load, it will also diminish the stim-
ulus for vagal afferent signalling to the NTS. Which of the
two mechanisms – direct inhibition of the vagal afferent
system or reduction of stimulus strength – is more rele-
vant cannot be decided without electrophysiological char-
acterization of the effect of H2 receptor antagonists on the
vagal afferent system.
A direct analysis of the gastroprotective effect of lafutidine
in the current study was out of scope because the gastric
acid load used here (0.25 M HCl) induced only minimal
gastric damage that was indistinguishable from that seen
after intragastric administration of saline [2]. As a conse-
quence, gastric acid-induced injury remained unaltered by
lafutidine in study 1, although there was a tendency
towards suppression of gastric lesion formation. Analysis
of the time course of the effect of lafutidine in study 2,
however, revealed that lafutidine, unlike vehicle, acceler-
ated the recovery from HCl-induced gastric damage.
The gastroprotective potential of lafutidine is further
envisaged from its effect to enhance intragastric pH and to
reduce gastric acidity following exposure to an exogenous
acid load. Since, as discussed above, endogenous gastric
acid secretion is suppressed by an exogenous acid load as
high as 0.25 M HCl, the action of lafutidine to decrease
gastric acidity may be the result of dilution, neutralization
or emptying of the acid load into the duodenum. It has
previously been found that exposure of the stomach to
supraphysiological concentrations of acid inhibits gastric
emptying and causes fluid secretion [2,9], which in the
current study was mirrored by the relatively slow decrease
of the gastric volume over the 2 h interval post-HCl.
Lafutidine and cimetidine appeared to accelerate gastric
emptying during the period 60 – 120 min post-HCl as
indirectly deduced from a decrease in gastric volume that
was more pronounced than in vehicle-treated animals. In
contrast, the gastric volume immediately after gastric acid
loading was significantly increased by lafutidine and
cimetidine, which suggests that the secretion of gastric
fluid was enhanced. The effect of lafutidine to reduce gas-
tric acidity during the period of 60 – 120 min post-HCl
coincided with its apparent effect to accelerate gastric
emptying. Apart from this mechanism of action it is alsoPage 9 of 11
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The capacity of lafutidine to stimulate secretory processes
other than acid secretion in the upper gut is supported by
its effect to increase acid-stimulated duodenal bicarbo-
nate secretion [7].
Cimetidine shared the effect of lafutidine to inhibit gastric
acid-evoked expression of c-Fos in the NTS [2] and mim-
icked, in a qualitative manner, the effects of lafutidine to
blunt gastric lesion formation, to decrease gastric acidity
and to initially enhance and later reduce gastric volume
following exposure to an exogenous acid load. The
smaller effect of cimetidine, relative to that of cimetidine,
is explained by its smaller potency as a H2 receptor antag-
onist [5].
Conclusion
Lafutidine has been shown to inhibit gastric acid-evoked
vagal nociceptive signalling and to decrease gastric acidity
following an exogenous acid load. The antinociceptive
effect of lafutidine may arise from an inhibitory effect on
acid-sensitive vagal afferent pathways, whereas the ability
of lafutidine to decrease the acidity of an exogenous acid
load may result from accelerated gastric emptying and
enhanced gastric fluid secretion. This profile of actions
appears to be shared by cimetidine, which implies that
histamine H2 receptor antagonists can protect the gastric
mucosa from acid injury independently of their ability to
suppress gastric acid secretion.
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